AU2002319381A1 - Use of antidiabetics for making a medicine with cicatrizing effect - Google Patents

Use of antidiabetics for making a medicine with cicatrizing effect

Info

Publication number
AU2002319381A1
AU2002319381A1 AU2002319381A AU2002319381A AU2002319381A1 AU 2002319381 A1 AU2002319381 A1 AU 2002319381A1 AU 2002319381 A AU2002319381 A AU 2002319381A AU 2002319381 A AU2002319381 A AU 2002319381A AU 2002319381 A1 AU2002319381 A1 AU 2002319381A1
Authority
AU
Australia
Prior art keywords
medicine
making
antidiabetics
cicatrizing
cicatrizing effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002319381A
Inventor
Philippe Briet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sante SAS
Original Assignee
Merck Sante SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0108130A external-priority patent/FR2826278B1/en
Application filed by Merck Sante SAS filed Critical Merck Sante SAS
Publication of AU2002319381A1 publication Critical patent/AU2002319381A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention concerns the use of at least an antidiabetic selected among compounds stimulation insulin secretion, glucosidase inhibitors, thiazolidine-diones, insulin, agents enhancing insulin sensitivity, the glucagon-like peptide-1 (GLP-1), PPAR alpha / gamma agonists, meglitinide and aP2 inhibitors for making a medicine with cicatrizing effect.
AU2002319381A 2001-06-20 2002-06-19 Use of antidiabetics for making a medicine with cicatrizing effect Abandoned AU2002319381A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29919601P 2001-06-20 2001-06-20
FR01/08130 2001-06-20
FR0108130A FR2826278B1 (en) 2001-06-20 2001-06-20 USE OF ANTIDIABETIC AGENTS FOR MANUFACTURING A MEDICAMENT HAVING A HEALING EFFECT
US60/299,196 2001-06-20
PCT/FR2002/002124 WO2003003971A2 (en) 2001-06-20 2002-06-19 Use of antidiabetics for making a medicine with cicatrizing effect

Publications (1)

Publication Number Publication Date
AU2002319381A1 true AU2002319381A1 (en) 2003-01-21

Family

ID=26213059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002319381A Abandoned AU2002319381A1 (en) 2001-06-20 2002-06-19 Use of antidiabetics for making a medicine with cicatrizing effect

Country Status (8)

Country Link
EP (1) EP1397124B1 (en)
AT (1) ATE346601T1 (en)
AU (1) AU2002319381A1 (en)
CY (1) CY1105822T1 (en)
DE (1) DE60216453T2 (en)
DK (1) DK1397124T3 (en)
ES (1) ES2275889T3 (en)
WO (1) WO2003003971A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
DE10214506A1 (en) * 2002-04-02 2003-10-16 Beiersdorf Ag Use of deoxynojirimycin and its derivatives for the treatment and prophylaxis of degenerative skin conditions
GB0303600D0 (en) * 2003-02-17 2003-03-19 Glaxo Group Ltd Novel therapeutic method and compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072527A (en) * 1959-07-01 1963-01-08 Horner Frank W Ltd Use of tolbutamide in the treatment of acne
DE2401450A1 (en) * 1973-01-16 1974-07-18 John James Voorhees PHARMACEUTICAL COMPOSITION FOR THE RELIEF OF SKIN PROLIFERATIONAL DISEASES
US4131652A (en) * 1977-06-22 1978-12-26 Deluccia Charles R Medicinal skin cream for psoriasis and method
US5145679A (en) * 1989-10-05 1992-09-08 Hinson Joan B Topical emollient for prevention and treatment of circulatory induced lesions
WO1993008815A1 (en) * 1991-10-28 1993-05-13 Cytoven Pharmaceutical dipeptide compositions and methods of use thereof
GB9701374D0 (en) * 1997-01-23 1997-03-12 Univ Liverpool Purinergic agonists and antagonists
US5929055A (en) * 1997-06-23 1999-07-27 The Research Foundation Of State University Of New York Therapeutic method for management of diabetes mellitus
JP2000212191A (en) * 1999-01-26 2000-08-02 Sankyo Co Ltd Phosphoric acid derivative
AR028299A1 (en) * 1999-09-17 2003-05-07 Novartis Ag A PHARMACEUTICAL COMPOSITION THAT INCLUDES NATEGLINIDA, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETY.
WO2001026639A2 (en) * 1999-10-08 2001-04-19 Novartis Ag Pharmaceutical composition of ateglinide and another antidiabeticagent
FR2802814B1 (en) * 1999-12-23 2002-02-22 Aventis Pharma Sa COMBINATION OF DEOXYFRUCTOSAZINE AND AN ANTIDIABETIC FROM THE SULFONYLUREA FAMILY
EP1272231A1 (en) * 2000-04-06 2003-01-08 University Technology Corporation Compositions and methods for promoting wound healing
AR030379A1 (en) * 2000-08-22 2003-08-20 Novartis Ag COMBINATIONS

Also Published As

Publication number Publication date
ES2275889T3 (en) 2007-06-16
DE60216453T2 (en) 2007-09-20
ATE346601T1 (en) 2006-12-15
DE60216453D1 (en) 2007-01-11
DK1397124T3 (en) 2007-04-02
WO2003003971A3 (en) 2003-12-04
EP1397124A2 (en) 2004-03-17
EP1397124B1 (en) 2006-11-29
CY1105822T1 (en) 2011-02-02
WO2003003971A2 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
DE69327309T2 (en) USE OF A PEPTID
IL188471A0 (en) Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
DE68929217T2 (en) INSULINOTROPES HORMON
ME00318B (en) Novel composition and use
EP1695983A3 (en) Glucagon-like peptide-1 analogs
ATE466028T1 (en) N-TERMINALLY MODIFIED GLP-1 DERIVATIVES
YU37301A (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
MXPA04001560A (en) Pre-mixes of glp-1 and basal insulin.
DE69326405T2 (en) Receptor for the glucagon-like peptide-1 (GLP-1)
EP1280531A4 (en) Local anesthetic methods and kits
EP1143989A3 (en) Methods for glucagon suppression
HUP0302529A2 (en) Glp-1 pusion proteins
ATE461217T1 (en) GLP-1 COMPOUNDS
DK1333887T3 (en) Combination therapy including antidiabetic and anticonvulsant agents
YU41402A (en) Trans olefinic glucokinase activators
AP2003002755A0 (en) Guanidinobenzamides as mc4-r agonists
CO5090908A1 (en) PROCEDURE FOR MANAGING INSULINOTROPIC PEPTIDES
BR0314655A (en) Combination drug
ES2549551T1 (en) Method of increasing bone hardness and stiffness and reducing fractures   
EA200401345A1 (en) TREATMENT OF GASTROPAREZES
MY155219A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide
AU2002319381A1 (en) Use of antidiabetics for making a medicine with cicatrizing effect
TR200000133T2 (en) Treatment of diabetes (diabetic) with thiazolidinedione, insulin secretagogue and alpha glucosidase inhibitor.
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
AR008025A1 (en) PHARMACEUTICAL COMBINATION OF A THIAZOLIDINDIONA AND AN INSULIN SECRETOGOGUE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase